deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04348656

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) (CONCOR-1)

A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)

Sponsor: Canadian Blood Services

Conditions COVID-19
Interventions Convalescent plasma
Updated 16 times since 2020 Last updated: Mar 1, 2022 Started: Mar 14, 2020 Primary completion: Mar 5, 2021 Completion: Jun 16, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated after the planned interim analysis as the pre-defined futility threshold was met

Other terminated trials from Canadian Blood Services

See all terminations from Canadian Blood Services

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

This PHASE3 trial investigates COVID-19 and is currently terminated or withdrawn. Canadian Blood Services leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Dec 2021 — Apr 2022 [monthly]

    Terminated PHASE3

▶ Show 11 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  2. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  5. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  6. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  8. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  9. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  10. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  11. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Blood Services
  • Hamilton Health Sciences Corporation
  • Héma-Québec
  • New York Blood Center
  • University of Toronto
  • Université de Montréal
  • Weill Medical College of Cornell University
Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Ajax, Canada , Bathurst, Canada , Brooklyn, United States , Calgary, Canada , Campbellton, Canada , Chicoutimi, Canada , Edmonton, Canada , Edmundston, Canada , Hamilton, Canada and 30 more locations